Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways. | Int J Mol Sci | 2023 | 37958702 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker. | Cancers (Basel) | 2023 | 37958409 | PubTator, text mining | PubMed |
| Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy-A Systematic Review. | Cancers (Basel) | 2023 | 37958406 | PubTator, text mining | PubMed |
| Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. | Mol Cancer | 2023 | 37951964 | PubTator, text mining | PubMed |
| Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma. | Hum Vaccin Immunother | 2023 | 37947202 | PubTator, text mining | PubMed |
| Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice. | Cell Commun Signal | 2023 | 37946301 | PubTator, text mining | PubMed |
| iTRAQ-based proteomics reveals potential markers and treatment pathways for acute Achilles tendon rupture. | J Orthop Surg Res | 2023 | 37946221 | PubTator, text mining | PubMed |
| VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy. | Cancer Cell Int | 2023 | 37936192 | PubTator, text mining | PubMed |
| Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors. | Front Immunol | 2023 | 37928556 | PubTator, text mining | PubMed |
| 13C tracer analysis reveals the landscape of metabolic checkpoints in human CD8+ T cell differentiation and exhaustion. | Front Immunol | 2023 | 37928527 | PubTator, text mining | PubMed |
| Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer. | J Transl Med | 2023 | 37925432 | PubTator, text mining | PubMed |
| BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells. | Cell Commun Signal | 2023 | 37924094 | PubTator, text mining | PubMed |
| Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. | Lancet Oncol | 2023 | 37922930 | PubTator, text mining | PubMed |
| Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis. | Cell Rep | 2023 | 37917583 | PubTator, text mining | PubMed |
| KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma. | Int J Gen Med | 2023 | 37916194 | PubTator, text mining | PubMed |
| Soluble immune checkpoints are elevated in patients with primary biliary cholangitis. | Eur J Med Res | 2023 | 37915081 | PubTator, text mining | PubMed |
| Acral melanoma: new insights into the immune and genomic landscape. | Neoplasia | 2023 | 37913653 | PubTator, text mining | PubMed |
| VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma. | Int Immunopharmacol | 2023 | 37907049 | PubTator, text mining | PubMed |
| The CD2-CD58 axis: A novel marker predicting poor prognosis in patients with low-grade gliomas and potential therapeutic approaches. | Immun Inflamm Dis | 2023 | 37904707 | PubTator, text mining | PubMed |
| An update on methods for detection of prognostic and predictive biomarkers in melanoma. | Front Cell Dev Biol | 2023 | 37900283 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=19